Trigeminal nerve

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Hello hay fever – why pressing under your nose could stop a sneeze but why you shouldn't

Retrieved on: 
Thursday, October 26, 2023

It is a protective reflex action outside our conscious control, to remove irritants from inside our nose.

Key Points: 
  • It is a protective reflex action outside our conscious control, to remove irritants from inside our nose.
  • You can sometimes stop a sneeze by holding your nose or pressing underneath it.
  • But given the velocity of a sneeze, it might not be a good idea to stop it after it has started.

An involuntary reflex

  • When a threshold amount of irritant signals reach the brain, the sneeze reflex is triggered.
  • A sneeze first involves a deep intake of breath and a build-up of pressure inside the airways.
  • This is then followed by contraction of the diaphragm and rib muscles, reflex closing of the eyes and a strong exhalation.

The trigeminal nerves

  • The trigeminal nerves are the largest of our 12 pairs of cranial nerves and the largest sensory nerves in the body.
  • The left and right trigeminal nerves carry sensory information from the face to the brain.

Sensory nerves communicate in the spinal cord

  • Sensory nerves travel to the brain via the spinal cord.
  • The sensory nerves that carry pain and irritant signals are narrow, whereas those that carry touch information are wider and faster.
  • In the spinal cord, these nerves communicate with each other via interneurons before sending their message to the brain.

So does putting your finger under your nose stop a sneeze?

  • These include pulling your ear, putting your tongue to the roof of your mouth or the back of your teeth, touching your nose, or even sticking your finger in your nose.
  • Read more:
    Forget nose spray, good sex clears a stuffy nose just as effectively — and is a lot more fun

But should you stop a sneeze?

  • Should you stop it?
  • Closing your mouth or nose during a sneeze increases the pressure in the airways five to 20 times more than a normal sneeze.
  • With no escape, this pressure has to be transmitted elsewhere and that can damage your eyes, ears or blood vessels.


The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore

Retrieved on: 
Tuesday, October 3, 2023

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA) , the national body that regulates medical devices, therapeutics, and other healthcare products.

Key Points: 
  • LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA) , the national body that regulates medical devices, therapeutics, and other healthcare products.
  • NeuroSigma recently announced its formation of a Singapore-based subsidiary (“NeuroSigma Singapore”).
  • The HSA approval means that NeuroSigma Singapore can commence marketing of its pioneering eTNS therapy device in Singapore.
  • The approval represents NeuroSigma’s first regulatory approval for the Monarch eTNS System in Asia and adds to its existing FDA approval in the United States.

CEFALY Technology Selected to Present TEAM Study Findings at the Military Health System Research Symposium

Retrieved on: 
Wednesday, August 9, 2023

DARIEN, Conn., Aug. 9, 2023 /PRNewswire/ -- Medical device maker CEFALY Technology will present findings from the TEAM (a phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine) study at the Military Health System Research Symposium (MHSRS) August 14-17, 2023, in Kissimmee, FL.

Key Points: 
  • DARIEN, Conn., Aug. 9, 2023 /PRNewswire/ -- Medical device maker CEFALY Technology will present findings from the TEAM (a phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine) study at the Military Health System Research Symposium (MHSRS) August 14-17, 2023, in Kissimmee, FL.
  • MHSRS is the Department of Defense's foremost scientific meeting and the premier venue for presenting new scientific knowledge resulting from military-unique research and development.
  • The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related healthcare initiatives.
  • "CEFALY Technology is proud to partner with VA Health Care to provide clinically proven, drug-free migraine treatment to veterans," said Jen Trainor McDermott, CEO of CEFALY Technology.

Northwell Health Commits $1M to Fund Employee Ideas for Healthcare Innovation During Big Ideas Showcase

Retrieved on: 
Monday, May 8, 2023

Northwell Health has awarded $1 million toward the research and development of two employee-driven projects that drive the goal of transforming the future of health care with new ideas during the health system’s 2023 Innovation Challenge.

Key Points: 
  • Northwell Health has awarded $1 million toward the research and development of two employee-driven projects that drive the goal of transforming the future of health care with new ideas during the health system’s 2023 Innovation Challenge.
  • Winners of the competition included team leads hailing from the Feinstein Institutes for Medical Research , the home of research at Northwell Health.
  • The announcement was made during the health system’s Made for Big Ideas™ Showcase.
  • To date, Northwell has awarded funding for 13 projects to advance their progress and develop their innovative ideas.

Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal

Retrieved on: 
Tuesday, January 17, 2023

“Our collaborative project will determine the efficacy of tAN to ease tapering of real-world patients from opioid management of chronic pain with reduced withdrawal symptoms.

Key Points: 
  • “Our collaborative project will determine the efficacy of tAN to ease tapering of real-world patients from opioid management of chronic pain with reduced withdrawal symptoms.
  • Importantly, neurostimulation therapy will provide a much needed and innovative treatment option over existing opioid analgesics with high risk for misuse, opioid use disorder, and overdose.”
    Amid the opioid epidemic, a treatment chasm has emerged.
  • Countless patients are being encouraged to avoid or discontinue opioid use for acute pain relief and chronic pain conditions for which opioids are a daily necessity.
  • Spark Biomedical developed the Sparrow Therapy System—the first FDA-cleared wearable, non-invasive tAN device for the treatment of opioid withdrawal.

CeCe Migraine Management App Syncs With CEFALY Connected Device to Provide Personalized Migraine Insights

Retrieved on: 
Wednesday, January 18, 2023

DARIEN, Conn., Jan. 18, 2023 /PRNewswire/ -- The award-winning CeCe Migraine Management app now offers users an unprecedented level of insight into their migraine treatments with the CEFALY Connected device.

Key Points: 
  • DARIEN, Conn., Jan. 18, 2023 /PRNewswire/ -- The award-winning CeCe Migraine Management app now offers users an unprecedented level of insight into their migraine treatments with the CEFALY Connected device.
  • The latest version of the CeCe app pairs with the Bluetooth-enabled CEFALY Connected so users can track CEFALY treatments and log migraine attacks on their mobile device.
  • When a user pairs their CEFALY Connected device with the CeCe app, they can:
    Download a PDF report with their unique migraine patterns and treatment data to share with healthcare providers.
  • "When used in conjunction with the CEFALY Connected, however, the CeCe app gives users the ability to truly understand their migraine treatment journey.

CEFALY Technology Launches Trade-In Program for Purchasers of the New CEFALY Connected Migraine Treatment Device

Retrieved on: 
Tuesday, December 20, 2022

It syncs with the CeCe Migraine Management app, giving users the ability to track CEFALY sessions and log migraine attacks on their mobile device.

Key Points: 
  • It syncs with the CeCe Migraine Management app, giving users the ability to track CEFALY sessions and log migraine attacks on their mobile device.
  • CEFALY, which was first introduced in 2008, is the only FDA-cleared migraine treatment device used for the treatment and prevention of migraine that is available without a prescription.
  • "The CEFALY Connected delivers the same clinically proven migraine treatment and prevention as earlier devices, while also empowering users with personalized insights into their treatment history and migraine patterns."
  • CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain.

CEFALY Technology Introduces Bluetooth-Enabled CEFALY Connected Migraine Treatment Device

Retrieved on: 
Thursday, December 15, 2022

DARIEN, Conn., Dec. 15, 2022 /PRNewswire/ -- Medical device maker CEFALY Technology today unveiled the newest evolution of its FDA-cleared migraine treatment device: the CEFALY Connected.

Key Points: 
  • DARIEN, Conn., Dec. 15, 2022 /PRNewswire/ -- Medical device maker CEFALY Technology today unveiled the newest evolution of its FDA-cleared migraine treatment device: the CEFALY Connected.
  • Representing a huge leap forward in drug-free migraine treatment technology, the Bluetooth-enabled CEFALY Connected syncs with the CeCe Migraine Management app, allowing users to track CEFALY treatments and log migraine attacks on their mobile device.
  • "The CEFALY Connected represents the most significant advance in drug-free migraine treatment in years," said Jen Trainor McDermott, CEO of CEFALY Technology.
  • CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain.

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 10, 2022

During the third quarter of 2022, the Company also disclosed an additional target and further indications for its ETF gene therapy program.

Key Points: 
  • During the third quarter of 2022, the Company also disclosed an additional target and further indications for its ETF gene therapy program.
  • Cash Position: As of September30, 2022, cash and cash equivalents was $68.8 million, compared to $104.9 million as of June 30, 2022.
  • Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • The tender offer for the outstanding common stock of Oyster Point Pharma Inc. (OP) has not yet been commenced.